Skip to main content

Table 2 Main patient's characteristics according to HBV treatment history

From: Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study

  Never treated Past treatment Currently treated p
  (n?=?40, 17.9%) (n?=?66, 29.6%) (n?=?117, 52.5%)  
Demographics     
Sex ratio M/F 26/13 54/11 98/17 0.03
Age m ± sd 38.7 ± 9.3 40.6 ± 10.0 43.8 ± 8.0 0.007
Country of origine     
Europe 13 (40.6) 38 (65.5) 57 (60.6) 0.007
North Africa 1 (3.1) 2 (3.4) 14 (14.9)
Sub-Saharan Africa 14 (43.8) 17 (29.3) 21 (22.3)
Other 4 (12.5) 1 (1.7) 2 (2.1)
Source of infection     
MSM 10 (29.4) 25 (42.4) 50 (51.0)  
IVDU 2 (5.9) 10 (16.9) 10 (10.2) 0.045
Heterosexual 19 (55.9) 21 (35.6) 34 (34.7)  
Other 3 (8.8) 3 (5.1) 4 (4.1)  
Current HAART 1 (2.5) 37 (56.1) 112 (95.7) <0.001
Liver disease     
ALT: m ± sd 56.2 ± 67.3 61.7 ± 68.4 89.2 ± 191 0.15
Metavir A >1 (83) 2 (20.0) 10 (43.5) 19 (38.0) 0.43
Metavir F ≥2 (94) 9 (64.3) 13 (52.0) 21 (38.2) 0.16
Viral and immunological markers    
HBV VL log UI/mL: m ± sd 5.0 ± 1.7 5.6 ± 1.9 5.7 ± 1.9 0.16
HBe Ag + 22 (59.5) 19 (32.8) 25 (25.0) <0.001
HDV+ 1 (2.5) 5 (7.9) 7 (6.1) 0.72
HCV+ 4 (2.6) 7 (11.5) 18 (16.1) 0.23
HIV VL log UI: m ± sd 4.0 ± 1.4 2.9 ± 1.5 2.7 ± 1.5 <0.001
CD4 count: m ± sd 398 ± 223 360 ± 266 372 ± 301 0.41
Genotype     
A 16 (40.0) 39 (59.1) 61 (52.1) 0.02
D 6 (15.0) 9 (13.6) 21 (17.9)
E 16 (40.0) 15 (22.7) 21 (17.9)
G 0 (0) 2 (3.0) 13 (11.1)
Other 2 (4.1) 1 (2.9) 1 (0.7)
Resistance associated mutations
Mutation rt173 0 6 (9.1) 16 (13.7) 0.04
Mutation rt180 1 (2.5) 22 (33.3) 41 (35.0) <0.001
Mutation rt181 0 0 5 (4.3) 0.28
Mutation rt204 1 (2.5) 22 (33.3) 35 (29.9) <0.001